Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.
作者信息
Naccarelli Gerald V, Peacock Frank
机构信息
Penn State Heart and Vascular Institute, Hershey, Pennsylvania 17033-3907, USA.
出版信息
Vasc Health Risk Manag. 2009;5:783-91. Epub 2009 Sep 18.
Abstract
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of cardiovascular morbidity and mortality, especially due to ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its involvement in both of these processes. Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.
摘要
相似文献
1
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.
Vasc Health Risk Manag. 2009;5:783-91. Epub 2009 Sep 18.
2
Atrial fibrillation: Blockade of the renin-angiotensin system in atrial fibrillation.
Nat Rev Cardiol. 2010 Aug;7(8):428-30. doi: 10.1038/nrcardio.2010.103.
3
The role of renin angiotensin system blockade in the treatment of atrial fibrillation.
Curr Drug Targets Cardiovasc Haematol Disord. 2005 Oct;5(5):387-403. doi: 10.2174/156800605774370317.
4
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31.
5
Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?
Expert Opin Pharmacother. 2005 Oct;6(13):2193-207. doi: 10.1517/14656566.6.13.2193.
6
The impact of suppressing the renin-angiotensin system on atrial fibrillation.
J Clin Pharmacol. 2006 Jan;46(1):21-8. doi: 10.1177/0091270005283284.
7
[Atrial fibrillation and renin-angiotensin system].
Nihon Rinsho. 2007 Mar;65(3):569-74.
8
Atrial fibrillation and renin-angiotensin system.
Ther Adv Cardiovasc Dis. 2008 Jun;2(3):215-23. doi: 10.1177/1753944708092111.
9
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
J Hypertens. 2007 Jan;25(1):15-23. doi: 10.1097/01.hjh.0000254378.26607.1f.
10
[The effect of inhibition of renin-angiotensin system on cardioversion success and recurrences of atrial fibrillation].
Anadolu Kardiyol Derg. 2009 Dec;9(6):505-11.
引用本文的文献
1
Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy.
J Am Heart Assoc. 2022 Aug 2;11(15):e026634. doi: 10.1161/JAHA.122.026634. Epub 2022 Jul 19.
2
Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.
World J Hypertens. 2012 Aug 23;2(4):34-44. doi: 10.5494/wjh.v2.i4.34.
本文引用的文献
1
Valsartan for prevention of recurrent atrial fibrillation.
N Engl J Med. 2009 Apr 16;360(16):1606-17. doi: 10.1056/NEJMoa0805710.
2
Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium.
Eur J Heart Fail. 2008 Dec;10(12):1172-6. doi: 10.1016/j.ejheart.2008.09.014. Epub 2008 Nov 7.
3
The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-Is and ARBS.
Br J Clin Pharmacol. 2008 Sep;66(3):345-51. doi: 10.1111/j.1365-2125.2008.03234.x.
4
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
Am J Hypertens. 2008 Sep;21(9):1034-9. doi: 10.1038/ajh.2008.217. Epub 2008 Jun 19.
5
Telmisartan, ramipril, or both in patients at high risk for vascular events.
N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
6
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
J Cardiovasc Pharmacol. 2008 Mar;51(3):217-22. doi: 10.1097/FJC.0b013e318160b42a.
7
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
J Hypertens. 2008 Mar;26(3):403-11. doi: 10.1097/HJH.0b013e3282f35c67.
8
The predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled study.
Cardiology. 2008;111(1):30-5. doi: 10.1159/000113424. Epub 2008 Feb 1.
9
Status of the epidemiology of atrial fibrillation.
Med Clin North Am. 2008 Jan;92(1):17-40, ix. doi: 10.1016/j.mcna.2007.09.002.
10
Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design.
Clin Drug Investig. 2007;27(10):697-705. doi: 10.2165/00044011-200727100-00005.
Zotero 插件